Skip Navigation

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Meinertz, T.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Meinertz, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Mibefradil — a drug which may enhance the propensity for the development of abnormal QT prolongation

T. Meinertz*

Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany

* Correspondence: Thomas Meinertz, MD, Abteilung für Kardiologie, Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, D-20246 Hamburg, Germany.

Abstract

Mibefradil is a moral calcium antagonist that is selective for the T-type voltage-operated calcium channel. It has been shown to be effective in hypertension and in stable angina. Shortly following its introduction, mibefradil was withdrawn from the market because of potentially harmful interactions with other drugs. Of special interest is the possible interaction of mibefradil with drugs which prolong the QT interval (e.g. amiodarone, quinidine, sotalol, erythromycin, desimipramine and thioridazine).

This short review summarizes the effects of mibefradil on cardiac repolarization and possible implications for drug interactions with QT prolonging agents.

Key Words: Mibefradil • cardiac repolarization • drug interactions

References

  1. Stockwell ML, Carlson A. Protecting Patients from Harm: Terfenadine and potential drug therapy interactions. Drug Information Journal. 1998;32:339–345
  2. Bernink PJLM, Prager G, Schelling A, Kobrin J. Antihypertensive Properties of the Novel Calcium Antagonist Mibefradil (Ro 40-5967). A New Generation of Calcium Antagonist? Hypertension. 1996;:27
  3. Mishra S, Hermsmeyer K. Selective Inhibition of T-type Ca 21 Channels by Ro 40-5967. Circulation. 1994;75:144–148
  4. Levine TB, Bernink PJLM, Caspi A, et al. Effect of Mibefradil, a T-Type Calcium Channel Blocker on Morbidity and Mortality in Moderate to Severe Congestive Heart Failure. The MACH-1 Study. Circulation. 2000;101:758–764[Abstract/Free Full Text]
  5. SoRelle R. Withdrawal of Posicor from Market. Circulation. 1998;98:831–832[Free Full Text]
  6. Wan Po AL, Zhang WY. What lessons can be learnt from withdrawal of mibefradil from the market? Lancet. 1998;351:1829–1830[CrossRef][Web of Science][Medline]
  7. Eightieth Meeting of The Cardiovascular and Renal Drugs Advisory Committee. Washington, DC: Associated Reporters of Washington; 1998.

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Meinertz, T.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Meinertz, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?